C2 Pharma doubles down on supplies of digoxin API

Luxembourg-based C2 Pharma, which already has a manufacturing agreement with Laurus Labs in India, has now bought a new supply of digoxin API. (Lauras Labs)

C2 Pharma, which concentrates on hard-to-make ingredients, has picked up a new supply of digoxin. The deal will give it two supplies of API for making the sometimes-difficult-to-get drug.

The Luxembourg-based company has acquired the digoxin API product portfolio of Polish company Nobilus. The company said that through the agreement, C2 Pharma is the product owner and Nobilus is a manufacturing partner and releasing entity for the API. Terms of the deal were not disclosed.

“While this type of investment is unprecedented for such a niche product, we believe that it is the most responsible path to secure a quality, continuous supply of this complex and essential API,” C2 Pharma CEO Andrew Badrot said in a statement.  

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

He pointed out that because of tighter regulatory oversight and the impurity and supply chain issues of some makers, supplies of digoxin APIs have been difficult for drugmakers to get since 2014.

C2 Pharma already has a long-term supply agreement and partnership with Indian API maker Laurus Labs. Last fall, the two validated the manufacturing process for two APIs, digoxin and digoxin micron, at a dedicated manufacturing facility at Laurus Labs' site in Vizag, India. In 2016, C2 invested about $10 million to build the 1,800-square-meter facility. It says the annual production of that facility equals the entire global demand for digoxin.

The company says that with the parallel manufacturing by Nobilus and Laurus, C2 Pharma can ensure redundancy and constant supply.

Suggested Articles

Alcon has many "mass and structural advantages" over "distant" follower Bausch, which spends a lot less on R&D, says one analyst.

The judge in a multistate case against opioid makers scoffed at their request for more time to review an estimate that they owe $480 billion in damages.

Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.